Navigating DED with Seasoned Patients

Dry eye disease (DED) significantly affects older individuals, with 5–30% prevalence in those over 65. The complexities of treating DED in older patients arise from interrelated factors including age-related physiological changes, systemic conditions, and changes in medication. Careful assessment of each patient's health history ensures tailored treatment plans that address not only the DED but also other health considerations, such as diabetes or autoimmune disorders. Effective management includes adapting medication choices and ensuring the practicality of therapy for the patient's capabilities.

About the Author(s)

Cecelia Koetting

Cecelia Koetting, OD, FAAO, DipABO, is an Assistant Professor at University of Colorado in Denver and a lecturer on ocular surface disease. Disclosures: Alcon, Allergan, Azura, B&L, BlinkJoy, Bruder, Claris Bio, Dompe, Glaukos, Harrow, Myze, Orasis, Oyster Point/Viatris, Tarsus, Topcon, Versea, and Vital Tears  

More Articles by Cecelia Koetting